Anthropic acquires AI biotech startup Coefficient Bio for $400M to expand into drug discovery and clinical workflows

Anthropic is making a decisive move into biotech. The AI company has acquired Coefficient Bio, a young AI startup focused on applying AI to drug development and clinical strategy, in a deal valued at roughly $400 million, according to an exclusive report from The Information.

The acquisition signals Anthropic’s growing ambitions beyond general-purpose AI, pushing deeper into life sciences where the stakes—and potential impact—are significantly higher.

“Anthropic has acquired AI biotech startup Coefficient Bio for roughly $400 million, The Information reported, citing a person with knowledge of the deal.

“The startup’s team will be joining Anthropic’s health care life sciences group, which is aimed at developing tools for biotech workflows ranging from drug discovery to clinical commercialization,”  The Information added.

Coefficient Bio’s team will join Anthropic’s healthcare and life sciences group, which is building tools to support biotech workflows from early-stage drug discovery through clinical commercialization.

Founded just last fall, Coefficient Bio was developing an AI platform designed to handle complex biotech tasks. That includes planning research and development pipelines, managing clinical and regulatory strategy, and identifying new drug opportunities.

The company was led by CEO Aris Theologis and CTO Nathan Frey, both of whom bring technical depth in applying AI to biological systems.

Why this matters

Anthropic’s move reflects a broader shift: AI companies are no longer just building models—they’re targeting entire industries.

Biotech stands out as one of the most promising frontiers. Drug development is expensive, slow, and data-heavy—exactly the kind of environment where AI can drive meaningful gains.

By bringing Coefficient Bio in-house, Anthropic gains not just talent, but a focused entry point into one of the most complex and high-value sectors AI can reshape.